Double Bond Pharmaceutical to present SI053 real-world evidence data at neuro-oncology meeting

Double Bond Pharmaceutical will present clinical real-world evidence (RWE) data for its lead neuro-oncology candidate, SI053 (Temodex), at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO). The meeting is scheduled for November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia.

The SNO Annual Meeting is recognized as a premier global event in the field of neuro-oncology. Double Bond Pharmaceutical's accepted abstract highlights the RWE data gathered concerning the SI053 candidate.

While specific details of the presentation content have not been disclosed, the acceptance into such a prominent industry gathering suggests the RWE data holds significance for neuro-oncology treatment strategies. The company previously announced an abstract acceptance for SI053 in June.

Further information regarding the conference and its agenda will be available through SNO's official channels. Double Bond Pharmaceutical is expected to provide more specific details on the presentation timing and content at a later date.